Face–Name Associative Memory Performance Among Cognitively Healthy Individuals, Individuals With Subjective Memory Complaints, and Patients With a Diagnosis of aMCI

Objective: The Face-Name Associative Memory Examination (FNAME) is a cross-modal associative memory test with a high sensitivity for detecting Alzheimer's disease-related subtle memory problems at an early preclinical stage. The present study examined the psychometric characteristics of a Greek version of the short form of FNAME (GR-FNAME12) to evaluate the contribution of demographic characteristics, report the range of performance within our sample, and estimate regression-based norms in cognitively normal elderly individuals. Method: In all, 216 cognitively normal elderly individuals were recruited and were administered a version of the short form of the FNAME (GR-FNAME12) that was culture and language specific to Greek-speaking individuals and developed for this study. Results: The construct validity of GR-FNAME12 was determined using principal component analysis thereby revealing two factors: face-name and face-occupation. These match the original version of the test. A significant positive correlation between GR-FNAME12 and two traditional memory measures - the RAVLT and the ROCFT - supported convergent validity. Test-retest reliability was computed for 32 participants. Multiple regression analyses showed that only age and not education or gender significantly predicted performance on the GR-FNAME12. We also estimated regression-based norms for the GR-FNAME12 scales. Conclusion: It was found that the Greek version of the FNAME12 had adequate psychometric properties, and could be administered to Greek-speaking individuals for clinical and research purposes.

This study examined the mediating role of basic psychological needs satisfaction in the relationship between attachment anxiety and depressive symptoms in university students. The following measurement instruments were used to collect the data: Center for Epidemiologic Studies—Depression Scale, Experiences in Close Relationships Scale and Basic Psychological Needs Satisfaction General—Scale. Mediated effects were explored using a series of regression analyses and were further confirmed through bootstrapping procedures. Results revealed that basic psychological needs satisfaction partially mediated the relationship between attachment anxiety and depression. These results indicated that attachment anxiety was connected with depressive symptoms in more complicated ways than had traditionally been suggested. Implications of the findings targeting basic psychological needs satisfaction in anxiously attached university students with higher levels of depressive symptoms for clinical practice are discussed.

Background/Objectives: SARS-CoV-2 can affect the central nervous system directly or indirectly. AD shares several similarities with long COVID cognitive impairment on a molecular and imaging level, as well as common risk factors. The objective of this review is to evaluate the incidence of post-acute COVID-19 cognitive impairment. Secondarily, we aim to determine if neuroinflammation in COVID-19 survivors may be associated with the onset of neurological disease, with a focus on Alzheimer’s disease (AD). Methods: literature search up to March 2025 on the prevalence of cognitive deficits in COVID-19 survivors, underlying pathophysiology and associations with neurological disorders. Results: a wide array of neuropsychiatric manifestations is associated with COVID-19; executive function, memory, and attention are the most frequently reported neurocognitive deficits, regardless of COVID-19 severity. There are associations between the risks for cognitive deficits post-infection with the age of the patients and the severity of the disease. Increasing evidence suggests that neurocognitive deficits are associated with the onset of neurological and neuropsychiatric disease in COVID-19 survivors. Conclusions: clinicians caring for COVID-19 survivors should actively investigate neurocognitive sequelae, particularly for patients with increased risk for cognitive deficits.